Trials / Terminated
TerminatedNCT02688790
Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection
Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 28 Days
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalbavancin |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2019-04-03
- Completion
- 2019-04-03
- First posted
- 2016-02-23
- Last updated
- 2022-03-29
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02688790. Inclusion in this directory is not an endorsement.